Top News

Europe Approves Novel Australian Drug Developed for Rare Sun Disease

Business Wire, 24.10.2014

The first new pharmaceutical drug invented and developed for an untreated disorder by any Australian company has received regulatory approval from the European Medicines Agency (EMA). SCENESSE® (afamelanotide 16mg) treats the debilitating genetic disorder porphyria (EPP), or absolute intolerance to sunlight. The fear of lifelong burns requires EPP patients to lead an indoor, isolated existence avoiding any form of light.


Next Event


Community Login

Bachem Holding AG

 Wissenschaft im Gespraech | Den Naturwissenschaften fehlt der Nachwuchs | Schweizer Radio DRS

The potential in the land

LRC TriCEPS™ technology

BBC - End of Drug Discovery